Genzyme and Isis reported this morning that in two late-stage studies mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo among patients with severe heterozygous familial hypercholesterolemia. "We are excited about the potential of mipomersen to help these patients, who are in great need of new treatment options," said Paula Soteropoulos, vice president and general manager of Genzyme's cardiovascular business. "We are committed to advancing our mipomersen development and commercialization plan to bring this uniquely targeted treatment to these patients, who are left behind by current treatments." Genzyme release